750. Combination aminoglycoside and beta-lactam therapy: strategies for emerging gram-negative bacteria
Session: Symposium: On the Shoulders of Giants
Friday, October 21, 2011: 2:40 PM
Room: 205ABC
Combination aminoglycoside and beta-lactam therapy : strategies for emerging
gram-negative bacteria

Session : On the Shoulders of Giants
There is still much debate about the role of combination therapy versus monotherapy for gram-negative infections.
Earlier studies have suggested that the bactericidal activity and synergistic effect of
beta-lactam in combination with aminoglycoside might be important in certain subsets of patients with such infections.  Moreover, combination therapy improves the likehood that a drug with in vitro activity against the suspected organism is being administered.
These considerations, and the search for innovative approaches, may become important as there is presently a dramatic increase in highly resistant gram-negative organisms, causing severe and potentially lethal hospital-acquired infections.  Compounding, this problem is the threat of a reduction in the discovery and development of new antibiotics, resulting in an alarming situation made of increasing drug resistance with absence of new drug development. 

J. Klastersky, MD, PhD 
Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles (ULB)


Jean Klastersky, MD, Jules Bordet Institute, Brussels, Belgium

Jean A - KLASTERSKY is born March 3, 1940, in Prague. Professor Klastersky has been Head of the Department of Medicine at the Institut Jules Bordet in Brussels and Professor of Medicine, Medical Oncology and Physical Diagnosis at the Université Libre de Bruxelles since 1977. He retired from these positions in 2005. Currently, he is the Coordinator of the “Programme des Soins Oncologiques” for the nine IRIS ( Interhospitalière Régionale des Infrastructures de Soins ) hospitals in Brussels and Consultant in medical oncology at the Institut Jules Bordet. Professor Klastersky was an intern and resident at the University Hospitals of the Université Libre de Bruxelles between 1962 and 1965, where he gained his MD (Docteur en Médecine, Chirurgie et Accouchements). From 1967 to 1968, he was Chief-Resident at Boston City Hospital and then a Research Fellow and Assistant in Medicine at Thorndike Memorial Laboratory Harvard Medical School. He became Chief of the Section of Infectious Diseases at the Institut Jules Bordet in 1970, before taking up the position of Head of the Department of Medicine in 1977. Professor Klastersky was a founder member of the European Lung Cancer Working Party and has been his President since 1978 until 2003. He was President (and founder member) of the International EORTC Antimicrobial Therapy Project Group between 1979 and 1987 and the Group’s Secretary General from 1987 to 2000. He was President (and founder member) of the Multinational Association for Supportive Care in Cancer (MASCC) from 1990 to 2000. He is Visiting Professor of Medical Oncology at the Charles University in Prague, since 1994. Professor Klastersky is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology, the American Society of Microbiology, the Infectious Diseases Society of America, the International Association for the Study of Lung Cancer, the “Royale Académie de Médecine” of Belgium and various other international and national medical and/or oncological societies. Professor Klastersky is the author of over 500 original articles, nearly 400 review articles and 17 scientific books. He is the Editor of Current Opinion in Oncology.

See more of: On the Shoulders of Giants
See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.